The scientists show that a specially engineered antibody can significantly enhance a group of medications that, despite early excitement, has had difficulty delivering on its initial potential. For two decades, cancer therapies known as CD40 agonist antibodies have raised hopes while repeatedly falling short. In laboratory animals, these drugs strongly stimulated immune attacks on tumors, […]
Source link